In our retrospective study in 77 MDS patients evaluated at various time points after AZA onset (but generally not before AZA), we established by FCM that a high percentage of BCL2L10 positive bone marrow mononuclear cells (BMMC) was significantly associated with a lower response rate and shorter survival [18]. The gene discussed is BCL2L10; the disease is myelodysplastic syndrome.